Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study
Vikas Gupta(Indian Institute of Technology Kanpur), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), John P. Galvin(Incyte (United States)), Adam J. Mead(National Institute for Health and Care Research), Rebecca B. Klisovic(Goethe University Frankfurt), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Abdulraheem Yacoub(The University of Kansas Cancer Center), John Mascarenhas(Tisch Hospital), Auro Viswabandya(Princess Margaret Cancer Centre), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Leah Price(Cwm Taf University Health Board), Amylou C. Dueck(Mayo Clinic in Arizona), Judith D. Goldberg(New York University), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Noushin Farnoud(Memorial Sloan Kettering Cancer Center)
Cited by 59
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k